Donald E. Mager

Dr. Donald E. Mager

Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JNJin Niu
Jin Niu
RSRobert M. Straubinger
Robert M. Straubinger
Donald E. MagerDonald E. Mager
Donald E. Mager

1 June 2006 in Biochemical Pharmacology
Verified
Journal Article
Closed access
Donald E. MagerDonald E. Mager
Donald E. Mager

1 January 2009 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
Donald E. MagerDonald E. Mager
Donald E. Mager
SWSukyung Woo
Sukyung Woo
WJWilliam J. Jusko
William J. Jusko
An important feature of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) models is the identification of drug- and system-specific factors that determine the intensity and time-course of pharmacological effects. This provides an opportunity to integrate information obtained from in vitro bioassays and preclinical pharmacological studies in animals to anticipate the clinical and adverse responses to drugs in humans. The fact that contemporary PK/PD modeling continues to evolve and seeks to emulate systems level properties should provide enhanced capabilities to scale-up pharmacodynamic data. Critical steps in drug discovery and development, such as lead compound and first in human dose selection, may become more efficient with the implementation and further refinement of translational PK/PD modeling. In this review, we highlight fundamental principles in pharmacodynamics and the basic expectations for in vitro bioassays and traditional allometric scaling in PK/PD modeling. Discussion of PK/PD modeling efforts for recombinant human erythropoietin is also included as a case study showing the potential for advanced systems analysis to facilitate extrapolations and improve understanding of inter-species differences in drug responses.

11 September 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JHJ M Harrold
J M Harrold
MRM Ramanathan
M Ramanathan
Donald E. MagerDonald E. Mager
Donald E. Mager

22 August 2012
Verified
Book Chapter
Open access
PDF file
MFMelanie A. Felmlee
Melanie A. Felmlee
MMMarilyn E. Morris
Marilyn E. Morris
Donald E. MagerDonald E. Mager
Donald E. Mager
Pharmacodynamic modeling is based on a quantitative integration of pharmacokinetics, pharmacological systems, and (patho-) physiological processes for understanding the intensity and time-course of drug effects on the body. Application of such models to the analysis of meaningful experimental data allows for the quantification and prediction of drug–system interactions for both therapeutic and adverse drug responses. In this chapter, commonly used mechanistic pharmacodynamic models are presented with respect to their important features, operable equations, and signature profiles. In addition, literature examples showcasing the utility of these models to adverse drug events are highlighted. Common model types that are covered include simple direct effects, biophase distribution, indirect effects, signal transduction, and irreversible effects.

6 January 2018 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
PBPeter Bloomingdale
Peter Bloomingdale
VNVan Anh Nguyen
Van Anh Nguyen
JNJin Niu
Jin Niu
Donald E. MagerDonald E. Mager
Donald E. Mager